These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27063550)

  • 21. Anorectic state of obesity medications in the United States. Are leaner times ahead?
    Li X; Bello NT
    Expert Opin Pharmacother; 2020 Feb; 21(2):167-172. PubMed ID: 31762335
    [No Abstract]   [Full Text] [Related]  

  • 22. Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches.
    Solas M; Milagro FI; Martínez-Urbistondo D; Ramirez MJ; Martínez JA
    Trends Pharmacol Sci; 2016 Jul; 37(7):575-593. PubMed ID: 27236593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity: pathophysiology and clinical management.
    Gurevich-Panigrahi T; Panigrahi S; Wiechec E; Los M
    Curr Med Chem; 2009; 16(4):506-21. PubMed ID: 19199918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current updates in the medical management of obesity.
    Khan A; Raza S; Khan Y; Aksoy T; Khan M; Weinberger Y; Goldman J
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):117-28. PubMed ID: 22435392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Past, Present, and Future of Pharmacologic Therapy in Obesity.
    Rodríguez JE; Campbell KM
    Prim Care; 2016 Mar; 43(1):61-7, viii. PubMed ID: 26896200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Horizons in the Pharmacotherapy of Obesity.
    Arch JR
    Curr Obes Rep; 2015 Dec; 4(4):451-9. PubMed ID: 26346394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of newer anti-obesity medications in a real-world setting.
    Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
    Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Rubio MA
    Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug strategies for the treatment of obesity.
    Alemany M; Remesar X; Fernández-López JA
    IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity: Current and potential pharmacotherapeutics and targets.
    Narayanaswami V; Dwoskin LP
    Pharmacol Ther; 2017 Feb; 170():116-147. PubMed ID: 27773782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy of obesity: An update.
    Cignarella A; Busetto L; Vettor R
    Pharmacol Res; 2021 Jul; 169():105649. PubMed ID: 33962014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of new-generation anti-obesity medications: a narrative review.
    Patel DK; Stanford FC
    Postgrad Med; 2018 Mar; 130(2):173-182. PubMed ID: 29388462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological management of obesity.
    Velazquez A; Apovian CM
    Minerva Endocrinol; 2018 Sep; 43(3):356-366. PubMed ID: 28462579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drugs to treat obesity: do they work?
    Kim S
    Postgrad Med J; 2016 Jul; 92(1089):401-6. PubMed ID: 27053517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of appetite suppression: implication for the treatment of obesity.
    Halford JC
    Curr Drug Targets; 2001 Dec; 2(4):353-70. PubMed ID: 11732637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
    Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological management of appetite expression in obesity.
    Halford JC; Boyland EJ; Blundell JE; Kirkham TC; Harrold JA
    Nat Rev Endocrinol; 2010 May; 6(5):255-69. PubMed ID: 20234354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy for the management of obesity.
    Patel D
    Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.
    Dong Z; Xu L; Liu H; Lv Y; Zheng Q; Li L
    Obes Rev; 2017 Dec; 18(12):1377-1385. PubMed ID: 29024559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.